Healthcare >> Analyst Interviews >> March 10, 2017

Positive Data Drives Early-Stage Biotech and Pharma Outperformance

Raja, Kumaraguru
Kumaraguru Raja, Ph.D., MBA, is Vice President, Biotechnology Research at Noble Life Science Partners. Dr. Raja has significant experience as an Equity Analyst in the health care industry with a focus on biotechnology sector. Previously, he was an Senior Associate Analyst for over five years on the Citi Research biotechnology team that has been continuously ranked highly for biotechnology in the All-America Institutional Investor survey. Dr. Raja's expertise includes bottom-up scientific, financial analysis on companies across therapeutic areas and spectrum of market capitalizations. Dr. Raja has strong quantitative, scientific background with in-depth biotechnology and health care industry knowledge leveraged to identify compelling investment opportunities. Dr. Raja has substantial experience working with leading U.S. institutional clients. He has deep knowledge of health care industry including drug development, intellectual property, FDA and EMA regulations, reimbursement coverage and clinical science. Dr. Raja conducted post-doctoral research at Mayo Clinic to understand the epigenetic causes of cancer and at Los Angeles Biomedical Research Institute to elucidate the molecular mechanisms concerning the role of human bone marrow stem cells in normal and leukemic hematopoiesis. He received his Ph.D. in biological sciences from Bowling Green State University and MBA from University of California, San Diego. Profile
TWST: Can you elaborate on the specifics of your coverage within biotechnology?

Dr. Raja: Our focus is on early-stage biotech/pharma companies. We tend to get

Pin It on Pinterest

Share This